Severe treatment-refractory T-cell-mediated immune skin toxicities observed with obinutuzumab/rituximab-atezo-pola in two patients with follicular lymphoma

Haematologica. 2020 May;105(5):e256-e260. doi: 10.3324/haematol.2019.233189. Epub 2020 Feb 6.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Humans
  • Lymphoma, Follicular* / drug therapy
  • Rituximab / adverse effects
  • T-Lymphocytes

Substances

  • Antibodies, Monoclonal, Humanized
  • Rituximab
  • obinutuzumab